DSP and Left ventricular dilatation: Individuals who possess high-risk genetic variants such as LMNA, FLNC, desmoplakin (DSP), and plakophilin-2 are at risk for malignant ventricular arrhythmias and sudden cardiac death, and should be evaluated for implantable cardioverter defibrillator (ICD) placement, regardless of their physical characteristics or left ventricular dilatation and systolic performance [175,176].